Detailed Findings
Biopharma Innovation
0%
36% say anti-obesity medication will have the biggest impact in 2025 on innovation in Biopharma
Unsurprisingly, anti-obesity medication has captured the attention of the world, with a clear majority, 36%, of our respondents selecting it as the area of innovation within Biopharma that is expected to have the biggest impact. The appetite is more pronounced across both Institutional Investors (42%) and Private Equity (44%) than Corporates (33%).
Target therapies and artificial intelligence have both seen a considerable drop in interest. Just 16% of respondents expect target therapies to have the biggest impact, down from the 35% of respondents who selected this last year. While 20% of respondents believed A.I. would have the biggest impact within Biopharma last year, just 8% thought so this year.
Jefferies Financial Group Inc. is the largest independent, global, full-service investment banking and capital markets firm headquartered in the United States. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. www.jefferies.com
IMPORTANT: You must read the following before reading, accessing or making any other use of this publication. In accessing this publication, you agree to be bound by the following terms and conditions. This document is being furnished for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase any security or other financial instrument or product. It is not intended to form the basis of any investment decision. Jefferies International Limited and its affiliates (together “Jefferies”) makes no representation as to the accuracy or completeness of the information contained herein or any other information, whether written or oral, made available. Jefferies disclaims all and any liability whatsoever, whether arising in tort, contract or otherwise, for the contents of this publication. You acknowledge that Jefferies does not owe you or any other person or entity, any fiduciary or similar duty as a result of the publication of this report, and Jefferies is not providing any advice, including with respect to legal, tax, accounting, investment or regulatory matters, in any jurisdiction.
